Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes

CONTEXT: Temozolomide (TMZ) is endorsed as the treatment of choice in aggressive or malignant pituitary adenomas. OBJECTIVE: Herein we describe a case of an aggressive prolactinoma that was resistant to TMZ. We performed a literature review of similar nonresponsive, aggressive prolactinomas. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Liza, Rai, Ashutosh, Salunke, Pravin, Ahuja, Chirag Kamal, Sood, Ashwani, Radotra, Bishan Dass, Sood, Ridhi, Korbonits, Márta, Dutta, Pinaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763612/
https://www.ncbi.nlm.nih.gov/pubmed/35059545
http://dx.doi.org/10.1210/jendso/bvab190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763612/
https://www.ncbi.nlm.nih.gov/pubmed/35059545
http://dx.doi.org/10.1210/jendso/bvab190

Ejemplares similares